Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Famitinib with Chemotherapy in First-line ES-SCLC
NCT06306560Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Sponsor
- Harbin Medical University
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Drugs
- adebrelimabfamitinib
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and famitinib in small cell lung cancer (SCLC), sponsored by Harbin Medical University. Primary endpoint: Progression-Free Survival at 6 months. Planned start Mar 2024; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Immuno-cherapy for extensive small cell lung cancer
Adebrelimab in combination with famitinib and chemotherapy
03
Who it enrols
Patients with pathologically confirmed extensive stage small cell lung cancer who have not received prior systemic therapy, with measurable disease and ECOG PS 0-1.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Progression-Free Survival
Objective Response Rate
Disease Control Rate
Overall Survival
Adverse Events
Quality of Life
Beyond the preview
Go deeper on NCT06306560.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06306560.